These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30121949)

  • 1. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
    Abeykoon JP; Zanwar S; Ansell SM; Winters J; Gertz MA; King RL; Murray D; Habermann T; Dingli D; Muchtar E; Go RS; Leung N; Inwards DJ; Buadi FK; Dispenzieri A; Lacy MQ; Lin Y; Gonsalves WI; Kourelis T; Witzig TE; Thompson C; Vincent Rajkumar S; Kyle RA; Kumar S; Kapoor P
    Am J Hematol; 2018 Nov; 93(11):1384-1393. PubMed ID: 30121949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
    Gustine JN; Meid K; Dubeau T; Hunter ZR; Xu L; Yang G; Ghobrial IM; Treon SP; Castillo JJ
    Br J Haematol; 2017 Jun; 177(5):717-725. PubMed ID: 28485115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.
    Menke MN; Feke GT; McMeel JW; Branagan A; Hunter Z; Treon SP
    Arch Ophthalmol; 2006 Nov; 124(11):1601-6. PubMed ID: 17102008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström macroglobulinemia.
    Gertz MA
    Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
    Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
    Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.
    Menke MN; Feke GT; McMeel JW; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):100-3. PubMed ID: 19362987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperviscosity syndrome in plasma cell dyscrasias.
    Mehta J; Singhal S
    Semin Thromb Hemost; 2003 Oct; 29(5):467-71. PubMed ID: 14631546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the hyperviscosity syndrome. II. Macroglobulinemia.
    MacKenzie MR; Babcock J
    J Lab Clin Med; 1975 Feb; 85(2):227-34. PubMed ID: 803540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
    Ito K; Kawasaki T; Hirano K; Sekiguchi N
    Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
    Ansell SM; Kyle RA; Reeder CB; Fonseca R; Mikhael JR; Morice WG; Bergsagel PL; Buadi FK; Colgan JP; Dingli D; Dispenzieri A; Greipp PR; Habermann TM; Hayman SR; Inwards DJ; Johnston PB; Kumar SK; Lacy MQ; Lust JA; Markovic SN; Micallef IN; Nowakowski GS; Porrata LF; Roy V; Russell SJ; Short KE; Stewart AK; Thompson CA; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Gertz MA
    Mayo Clin Proc; 2010 Sep; 85(9):824-33. PubMed ID: 20702770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of Waldenstrom macroglobulinemia in Korea.
    Bang SM; Park SR; Park SH; Cho EK; Yoon SS; Shin DB; Lee JH; Park S; Kim BK; Kim NK
    Korean J Intern Med; 2004 Sep; 19(3):137-40. PubMed ID: 15481603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
    Kyle RA; Benson JT; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Melton LJ; Rajkumar SV
    Blood; 2012 May; 119(19):4462-6. PubMed ID: 22451426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
    Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
    Menke MN; Feke GT; McMeel JW; Treon SP
    Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1157-60. PubMed ID: 18326744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic Waldenstrom's macroglobulinemia.
    Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
    Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia.
    Mullen EC; Wang M
    Clin J Oncol Nurs; 2007 Feb; 11(1):87-95. PubMed ID: 17441400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood viscosity in Waldenström macroglobulinemia.
    MacKenzie MR; Lee TK
    Blood; 1977 Apr; 49(4):507-10. PubMed ID: 402961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
    Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
    Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
    [No Abstract]   [Full Text] [Related]  

  • 20. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.